Tag: Medical Devices

NABH MITRA PROGRAM – Launch

Posted on by Leave a comment

LAUNCH OF NABH MITRA EMPANELMENT PROGRAMME (MEP)

The NABH MITRA Empanelment Programme has been officially launched to build a nationwide network of verified professionals and organisations (“MITRAs”) who will support hospitals with NABH Accreditation, Certification, and digital health transformation, especially across Tier 2, 3, and 4 cities in India.

The last date to submit applications for empanelment is October 10,2025

About the Programme

The initiative offers a structured, transparent framework for MITRAs—trusted companions to hospitals—who will guide healthcare organisations through quality improvement and digital enablement in line with NABH standards. Empanelled MITRAs will be listed on the NABH website with verified credentials and areas of expertise.

Categories of MITRAs

Digital MITRA: Supports hospitals in implementing NABH Digital Health Standards and IT enablement through structured digital health consultancy. Digital MITRA category has additional training and experience requirements

Organisational MITRAs: Support hospitals for both Full Accreditation and Entry-Level Certification.

Individual MITRAs: Independently support hospitals mainly for Entry-Level Certification.

Who Can Apply:

Individual MITRAs: Qualified professionals with at least one successful accreditation or certification support project and one NABH-certified professional (current assessors not eligible).

Organisational MITRAs: Registered companies, LLPs, trusts, societies, or proprietorship entities operational for at least one year, with experience supporting minimum three hospitals through accreditation or certification. Must have at least two NABH-certified professionals (current NABH assessors not eligible).

Application Process & Fees

i. Apply via the NABH online portal by October 10, 2025.
ii. Shortlisted candidates will be invited for interviews and required training.
iii.Empanelment fee for a three-year period: ₹20,000 + GST (Individual MITRA), ₹50,000 + GST (Organisational MITRA).
iv.Training program charges: ₹25,000 + GST for MITRA, ₹15,000 + GST for Digital MITRA (paid after selection)

Additional Information

i. MITRAs will play a key role in enabling hospitals to achieve NABH standards and strengthen India’s healthcare quality framework
ii. Empanelment does not imply endorsement or financial association by NABH.
iii.Maintaining high standards, transparency, and ethical conduct is compulsory.

Download NABH Concept Note

Source: https://portal.nabh.co/Announcement/MEP_Concept.pdf

Industry update: Constitution of Medical Device related adverse Event Committee in Medical Colleges

Posted on by Leave a comment

Constitution of Medical Device related Adverse Event Committee in each Medical College

The National Medical Commission (NMC) public notice, dated July 13, 2025, addresses the monitoring, assessment, and prevention of adverse events associated with medical devices through the constitution of a Medical Device related Adverse Event Committee (MDAEC) in each medical college.

Here’s a breakdown of the advisory:

Intent of the Advisory:

The core intent of this advisory is to enhance patient safety and improve the quality of healthcare delivery by systematically collecting, analyzing, and responding to adverse events related to medical devices. It acknowledges that medical devices are crucial in modern healthcare but can cause harm, necessitating a robust monitoring system. The advisory emphasizes the integration of medical colleges into the Materiovigilance Programme of India (MvPI), launched in 2015 by the Ministry of Health and Family Welfare (MoHFW), to monitor these adverse events and risks nationwide. This program aims to provide data to the Central Drugs Standard Control Organization (CDSCO) to support regulatory action and guide improvements in clinical practice.

Role of Medical Colleges:

Medical colleges are identified as ideal hubs for Materiovigilance due to their diverse patient populations and access to advanced healthcare technologies.

The advisory outlines several strategic advantages for medical colleges becoming a Medical Device Adverse Events Monitoring Centre (MDMC), including:

Academic Recognition: Enhancing the institution’s stature as a contributor to national public health and regulatory science.
Professional Development: Providing faculty and students hands-on exposure to post-market surveillance, risk assessment, and patient safety.
Infrastructure Enhancement: Gaining access to MvPI resources, training modules, and national-level collaboration.
Policy Influence: Offering opportunities to contribute to evidence-based recommendations and medical
device regulations.
Patient Safety: Ensuring early detection and response to device malfunctions, directly improving clinical outcomes.

Key Directives for Medical Colleges:

The advisory mandates the following actions for all medical institutions:

Establishment of MDAEC: Each medical institution is advised to set up a committee to monitor adverse events related to medical devices.
Registration with IPC: This committee must be registered with the Indian Pharmacopoeia Commission (IPC). The enrollment form is available on the IPC website.
Website Disclosure: The medical institution’s website must indicate the name of the Coordinator/Convenor and additional members of the committee.
Chairperson: The Medical Superintendent will ordinarily be the Chairperson of this committee.
Registration Date: The website should also indicate the date of MDAEC registration.
Pharmacovigilance Committee Update: Institutions are also reminded to update the names of Pharmacovigilance Committee members on their website.

Timeline: This process has to be completed before July 31, 2025.

Source:https://www.nmc.org.in/MCIRest/open/getDocument?path=/Documents/Public/Portal/LatestNews/Public%20Notice%20dt%2013-07-2025.pdfhttps://www.nmc.org.in/MCIRest/open/getDocument?path=/Documents/Public/Portal/LatestNews/Public%20Notice%20dt%2013-07-2025.pdf

Industry Information Update – BIS – Sector wise Calendar for Upcoming Webinars

Posted on by Leave a comment

BIS – Sector wise Calendar for Upcoming Webinars

Bureau of Indian Standards is organising Sector specific awareness programs

In order to spread the awareness among the concerned stakeholders, manufacturers, importers and common consumers BIS is organising ‘Interactive lecture series and Sector-wise webinar’ on the below mentioned topics.

Manufacturers including MSMEs are requested to attend the above webinars based on their respective business interests for a particular sector.

Participation in these webinars does not require any preregistration and can be joined conveniently and remotely through Computer / Laptops / Mobiles.

The link for joining these webinars are hosted well in advance on BIS Website: www.bis.gov.in

Source: https://www.bis.gov.in/

Industry Information Update – HOSPEX–QAI Quality Culture Award 2025

Posted on by Leave a comment

HOSPEX–QAI Quality Culture Award 2025

4th Edition of  HOSPEX Healthcare Expo cum Conferences will be held at Kochi, Kerala from Aug 22nd – 24th 2025. This is Kerala’s first B2B Medical Expo which will take place at KINFRA International Exhibition Centre, Kakanad, Kochi, Kerala

As a part of the Expo, to encourage, nurture the Culture of Practicing Quality in Small Hospitals, Hospex-QAI Quality Culture Award 2025 is designed this year.

About the Award:

The award is a joint initiative of HOSPEX India and QAI.

This award is a recognition of the Quality Focus that is built in Small Hospitals and the efforts taken by Small Hospitals to make Quality a Culture in their clinical settings.

For any Practice to become a Culture needs lot of commitment in any organisation. This award is created to motivate healthcare facilities to come forward and pitch their Quality Practices which have become a Culture in their settings.

About HOSPEX:       

Hospex is the initiative of Trithvam Integris, a company that specialises in managing Health and Medical Fair Events. Hospex is solely focused on digital health, healthcare and organising conferences for the medical industry by a group of doctors.

HOSPEX 2025 is the only Medical & Healthcare Exhibition in Kerala targeting Hospitals, Other Healthcare organisations, Medical Device Manufacturers, Pharmaceutical Manufacturers, Startups, Innovators in Health Tech and Med tech space.

The core focus of HOSPEX Healthcare Expo 2025 (Fourth Edition) is Medical Knowledge dissemination thereby hosts multitude of conferences focused on the futuristic trends in the medical industry. These conferences provide attendees with the opportunity to learn about new products and technologies, network with other professionals in the field, and stay up-to-date on the recent and futuristic developments in the industry

About QAI – Quality & Accreditation Institute

Quality and Accreditation Institute (QAI) is an International Accreditation Body that provides Accreditation/ Certification to Healthcare Organisations (Hospitals, Clinics, Dental centres, Eye Clinics, Imaging centres, IVF centres, Dialysis centres, Home Care, Stroke centres, Telehealth services, Hair Transplant Centres, Bone Marrow Transplant centres, Rehabilitation centres, Ambulatory care centres etc.).

QAI provides a platform to stakeholders including professionals and organisations, associated with Quality in any way, to share their wisdom and Knowledge in order to make healthcare services delivering better outcomes.

QAI is closely working with stakeholders including Government agencies to support accredited healthcare facilities in terms of empanelment and other benefits.

Target Segment:

Any healthcare facility such as Hospitals, Clinics, Dental centres, Eye Clinics, Imaging centres, IVF centres, Dialysis centres, Home Care providers, Stroke centres, Telehealth services, Hair Transplant Clinics, Bone Marrow Transplant centres, Rehabilitation centres, Ambulatory care centres etc.).

Wellness Centres offering AYUSH Services

Applicants can be from Private or Government settings.

Eligibility Criteria:

  • Applicant must have implemented a Quality Management System/ Patient Safety Program/ any Certification or Accreditation Program for a minimum period of last 3 years continuously
  • QAI accredited healthcare facility will be given preference
  • Applicant can be from any part of India

Application Form Content:

  • To be filled in the format given
  • General Information about the Healthcare facility
  • Specific information about Quality Practices/ Certifications / Accreditation (Evidences to be submitted to support any such claims)
  • 2 case studies/ examples to demonstrate improvement/ patient safety in last 3 years
  • Language for submission – English

Application Fee:

  • Rs. 1180/- (including 18% GST) for each application

    To be payable to HOSPEX India’s account as shared below:

    Tritvam Integris Pvt. Ltd.
    GST No: 32AAJCT2250M1ZA
    Tritvam Integris, Jyothi Trade Centre, Chettupuzha, PO,  Thrissur – 680 012

Application Submission Date:
Last date for submitting applications: 10 August 2025.

Completed Application including payment proof to be mailed to:

Ms. Chandni Rohila
Accreditation Officer
Quality & Accreditation Institute (QAI)
709, Wave Silver Tower, Sector 18, Noida-201301, India
Ph. No.: +911206664981
M: +91 8287841146
Email – chandni@qai.org.in

Terms and Conditions:

  • Only completed applications will be taken up for evaluation.
  • Jury will comprise of experienced professionals with healthcare operations, management, quality, clinical background
  • Only one application per location is acceptable.
  • Applicants can save the completed application and all evidences on a google drive folder and can share the folder access link to QAI through email to chandni@qai.org.in.
  • Applications submitted after the last date will not be entertained.
  • Jury will evaluate the applications and decide on the winners of the Award.
  • Shortlisted applicants may be called for virtual presentation, if needed.
  • Winners will be announced by 12 August 2025.
  • Winers will have to travel to Kochi (Cochin), to collect their Awards in an event to be held on 23 August 2025.
  • Organisers will not make any travel, stay arrangements and winners have to make their own arrangements.
  • Decision of the Jury shall be final and binding on all.
Click here to download the application
Click here for Brochure

Source: https://hospex.in/

Industry Update – MoHFW Notification

Posted on by Leave a comment

Compounding of Offences under Drugs and Cosmetics Act , 1940 for Pharma and Drug Manufacturers

Ministry of Health and Family Welfare has released a gazette notification notifying the new rules that may be called the Drugs and Cosmetics (Compounding of Offences) Rules, 2025. The rules are framed by the Central Government using the powers conferred by the Drugs and Cosmetics Act, 1940.

The notification introduces rules under an existing act, under section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940).

These rules provide a framework for “compounding of offences” under the Drugs and Cosmetics Act, 1940. This means that instead of going through full prosecution, certain offences might be resolved by paying a specified amount (compounding amount). The rules outline the process for applying for compounding, the authorities involved, and the conditions for granting immunity from prosecution.

Key highlights of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025 notification:

Compounding of Offences: The primary focus is to establish rules for compounding certain offences under the Drugs and Cosmetics Act, 1940, offering an alternative to traditional prosecution.  

Application Process: The rules detail how an applicant (a company or person involved in the pharma industry) can apply for compounding of an offence. This can be done before or after prosecution begins.  

Compounding Authority: The notification defines the “compounding authority” and how they are appointed by the Central or State Government to manage the compounding process.  

Procedure: It outlines the step-by-step procedure the compounding authority must follow, including gathering reports and making decisions on whether to allow compounding.  

Immunity from Prosecution: The rules explain the conditions under which the compounding authority can grant immunity from prosecution to an applicant.  

Withdrawal of Immunity: The notification also specifies the circumstances under which this granted immunity can be withdrawn.  

Form for Application: The inclusion of a specific form for applying for compounding of offences

Why the need for “Compounding of Offences” ?

The Jan Vishwas (Amendment of Provisions) Act, 2023, aims to decriminalize various offenses in 42 Central Acts, enhancing ease of doing business and living by reducing compliance burdens. It accomplishes this by removing imprisonment and/or fines in many provisions, replacing them with penalties or enhancing existing fines. 

Key features and objectives of the Jan Vishwas Act include:

  • Decriminalization:The Act decriminalizes 183 provisions across 42 Central Acts, which are administered by 19 Ministries/Departments. 
  • Enhanced Ease of Doing Business:The Act aims to simplify compliance for businesses by removing or modifying existing criminal penalties. 
  • Trust-Based Governance:By decriminalizing certain offenses, the Act seeks to foster a more trust-based environment for businesses. 
  • Pragmatic Penalties:The Act introduces mechanisms for adjudicating officers and appellate authorities, ensuring penalties are commensurate with the severity of the offense. 
  • Flexibility in Enforcement:The Act allows for compounding of certain offenses, providing an alternative to full-fledged prosecution. 
  • Focus on Specific Acts:The Act addresses provisions in various Acts, including those related to intellectual property, media, and other sectors. 

Drugs and Cosmetics Act, 1940 Amendment: The Drugs and Cosmetics Act, 1940 is one of the acts amended by the Jan Vishwas Act.

Implementation of Jan Vishwas Act’s Intent: The Drugs and Cosmetics (Compounding of Offences) Rules, 2025, can be seen as a mechanism to implement the changes brought about by the Jan Vishwas Act to the Drugs and Cosmetics Act, 1940. It provides the specific procedures and framework for how these offenses will be dealt with, in alignment with the intent of decriminalization and promoting ease of doing business.

Overall, the Jan Vishwas Act aims to create a more business-friendly and less punitive environment by decriminalizing certain offenses and rationalizing legal provisions across various sectors. 

Hence the new Rules on Compounding of Offences under Drugs & Cosmetics Act may have originated from the recent amendments made to Jan Vishwas (Amendment of Provisions) Act 2023.

In essence, the Jan Vishwas Act provides the legislative amendment to allow for decriminalization, and the Drugs and Cosmetics (Compounding of Offences) Rules, 2025, provides the procedural rules for implementing that change through compounding of offenses.

Click to read the Notification

Industry Update – Revision of Risk based Classification of Medical Devices – CDSCO

Posted on by Leave a comment

Revision of Risk based Classification of Medical Devices – CDSCO

Central Drugs Standard Control Organisation (CDSCO) has revisited the existing risk based classification of Medical Devices in the categories of Cardiovascular and Neurological and added new entries based on their classification as per the First Schedule (Part I) of the MDR 2017

In this regard, CDSCO has issued a notification dated 1st April 2025, inviting all Stakeholders in the Medical Devices sector, such as Healthcare professionals, Manufacturers, Policymakers, Regulatory bodies, and other entities involved in the classification and regulation of medical devices to review the draft document and provide feedback within 30 days of publication to refine the risk-based classification framework for medical devices.

All concerned associations/stakeholders are requested to forward your comments by filling the Google form at https://forms.gle/62xF3BtXWC5pgD3TA within 30 days from the date of publication of this draft.

Click here for the List

Source: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTI2MjM=

Industry update – PRIP Scheme

Posted on by Leave a comment

PRIP Scheme’s
Expression of Interest (EOI)

The Department of Pharmaceuticals announces the launch of the Expression of Interest (EoI) under the Scheme for Promotion of Research & Innovation in Pharma, MedTech Sector (PRIP)

The EoI has been designed to provide you with an opportunity to co-shape India’s journey towards becoming an R&D innovation hub. All interested entities are encouraged to participate in PRIP Scheme’s Expression of Interest (EoI) process and share description of suitable projects.

Please visit the scheme’s website to access the EoI form: https://pharma-dept.gov.in/prip/

About the PRIP Scheme:

The PRIP Scheme aims to transform India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme has a total outlay of ₹5,000 Cr, of which ₹4,250 Cr is focused on accelerating investments in industry-led R&D projects within six priority research areas, including: New Chemical Entities, New Biological Entities and Phyto-pharmaceuticals, Complex generics and Biosimilars, Precision Medicine, Medical Devices, Orphan Drugs and Drug Development for Antimicrobial Resistance (AMR)

For any queries about the scheme or EoI process please write to us at support-prip@pharma-dept.gov.in

Source : https://www.linkedin.com/posts/pharma-dept_innovation-healthcare-pharmaceuticals-activity-7303677221112541184-9yrW?utm_source=share&utm_medium=member_desktop&rcm=ACoAAABYr-QBBx6RLFkUHnEgb2n9GcB2vrhm0cg

Scheme Overview

The Scheme for “Promotion of Research and Innovation in Pharma MedTech sector (PRIP)” has been launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, with the goal of transforming India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme has been notified vide Gazette Notification No. 199 dated 17th August 2023. The scheme has a total financial outlay of Rs. 5,000 Crores, of which Rs 4,250 Crores is focused on accelerating investments in the R&D ecosystem within the sector.

The scheme proposes funding across 6 priority areas and 3 funding categories:

Priority Areas
There are six priority research areas which will be covered by the PRIP scheme

  1. New Chemical Entity, New Biological Entity and Phyto-pharmaceuticals
  2. Complex generics and Biosimilars
  3. Precision medicine (Targeted innovative therapeutics)
  4. Medical devices
  5. Orphan Drugs
  6. Drug development for AMR

Key Funding Categories

R&D projects (focused on one or more of the priority areas above) need to be submitted within one of the following three funding categories:

1. B I: Funding up to 35% of total project cost or ₹125 Cr (whichever is less)

  • Applicants must be Pharmaceutical or MedTech companies with:
    o Annual revenue ≥ Rs. 1,000 Cr (Pharma) or ≥ Rs. 250 Cr (MedTech)
    o R&D expenditure of 3-5% (Pharma) or 1-3% (MedTech) of total revenue in the last five years
    o Collaboration with a Government Research Institution (See Appendix II for more details)
    o Projects in priority areas at any TRL 1 to 9

2. B II: Funding up to 35% of total project cost or Rs. 100 Cr (whichever is less)

  • Entities working on R&D projects in priority areas that are at TRL 5 or 6

3. B III: Funding up to Rs. 1 Cr per project

  • Startups and MSMEs working in priority areas at TRL 1 onwards to TRL 4
    For more information on TRL, kindly refer to the Appendix III of the EoI document

    Invitation for Expression of Interest
  • Department of Pharmaceuticals invites Expression of Interest (EoI) from interested entities – e.g.,
  • Proprietary Firm or Partnership Firm or Limited Liability Partnership (LLP), Startups or a Company /Group
  • of companies registered in India for project funding under the PRIP scheme.
  • This EoI has been designed to provide you with an opportunity to co-shape India’s journey towards
  • becoming an R&D innovation hub, by soliciting your inputs on:
  • Current R&D projects in the scheme’s priority areas for PRIP funding consideration
  • Challenges in execution of an R&D projects
  • Actions to strengthen the R&D ecosystem for Pharma and MedTech innovation in India
Download the EOI Document here

Source: https://pharma-dept.gov.in/prip/

Industry Updates : Import of refurbished medical devices are not allowed – CDSCO

Posted on by Leave a comment

Import of refurbished medical devices are not allowed – CDSCO

Central Drugs Standard Control Organisation (CDSCO) regulates Quality, Safety and Performance of the Medical Devices under Drugs and Cosmetics Act, 1940 and Medical Devices Rules 2017.


To control the second-hand / unregulated medical devices in the country, recently CDSCO has issued a letter to the Principal Commissioner of Customs, New Delhi, clarifying that No separate license is issued for import of refurbished medical devices in the country. Following points are covered in the communication

  1. All the Medical Devices are regulated under Medical Devices Rules 2017
  2. However, there is no specific provision for regulation of refurbished medical devices under the said Medical Devices Rules 2017         
  3. Hence no license is issued for import of such devices and it cannot be imported in the country under Medical Devices Rules 2017 for sale and distribution.
Click here to read more

Industry Update – ADVANCING TECHNOLOGY & INNOVATION IN INDIAN MEDICAL DEVICES AND ALLIED SECTORS

Posted on by Leave a comment

ADVANCING TECHNOLOGY & INNOVATION IN INDIAN MEDICAL DEVICES AND ALLIED SECTORS

The Indian medical devices market has been identified as a sunrise sector by the Government of India, with its valuation anticipated to reach USD 50 Billion by 2030 Ernst & Young India; 26 Nov., 2024.

Notwithstanding the enormous growth potential of Indian medical device sector, its global market share is still fairly low with most of the domestic manufacturing focused on consumable and disposables, i.e. the lower end of technology value chain.

Realizing this, Government has identified medical devices sector as a priority area for the flagship ‘Make in India’ program and is committed to strengthen the manufacturing ecosystem through its ambitious initiatives

Technology and Development Board (TDB) has also, over the years, supported development and commercialization of socially and technologically relevant medical devices. In order to strengthen country’s priority sectors, TDB is launching the current ‘Call for proposal’ to supplement existing policy initiatives to bridge the current medium to high technology gap in Indian medical devices industry..

Technology Development Board invites proposals from Indian industrial concerns operating in medical devices and allied sectors to apply for funding support for product development/ manufacturing/scale-up; technology adaptation for new product development; medical device supply chain components; chemical and raw materials for diagnostics and kits; and product commercialization

Objectives of the Call for Proposal

I. Identify and act in areas requiring strategic interventions and develop socially relevant technologies by increasing access and universality to affordable and quality medical and healthcare devices.

II. Encourage production of competitive consumer products thereby reducing import dependence by supporting manufacturing and commercialization of medium to high technology medical devices.

III. Invest in core technological strengths to enable Indian industry to stand-up to the competitive pressure and   accelerate country’s share of high-end, complex medical devices in global market.

Scope and focus areas

  • Diagnostics and Imaging devices: Including Radiology (both ionizing & non-ionizing radiation products); Nuclear Imaging Devices; Anesthetics & Cardio-Respiratory medical devices including catheters of cardio respiratory category; Renal Care medical devices; Artificial Intelligence based devices for detecting and monitoring lifestyle and other diseases.
  • Therapeutic and Prosthetics: Including cancer care/Radiotherapy devices; All Implants including prosthetic limbs/organs, implantable hearing aids/ear prosthesis; ophthalmic prosthetics (artificial eyeballs/cornea, eye socket replacements); voice prosthesis etc.
  • Regenerative therapy devices: Including cell therapies, immunomodulation therapies and tissue engineering (laboratory grown organs and tissues) related devices.
  • Medical equipment (others): All medical devices as classified under low risk (Class A) to high risk (Class D) categories in the Medical Devices Rules, 2017 and as detailed by Central Drugs Standard Control Organization on their website.

Eligibility Criteria:

  • Any Company incorporated under the Companies Act, 1956/the Companies Act, 2013.
  • A company intending to commercialize the technology.
  • The eligibility criteria and financial support shall be as per the TDB guidelines. Please refer to the website for more details: https://tdb.gov.in/project-funding-guidelinesfaqs 

Modes of Funding:

  • Loan @ 5% Simple Annual Interest

How to Apply:

All applications have to be submitted through online portal of TDB. The detailed information and the format for submission of the proposal may be downloaded from the official website: https://tdb.gov.in/

For queries and further details contact:

Dr. Richa Panwar
Sr. Project Coordinator
Technology Development Board
https:/tdb.gov.in/
Email: richa.panwar@tdb.gov.in

Starting date of call for Proposal: December 16, 2024

Last date to apply : 16th February 2025

Source: https://tdb.gov.in/

Industry Update – “MEDTECH QUALITY CHAMPION AWARDS”

Posted on by Leave a comment

CII-AMTZ
MEDTECH QUALITY CHAMPION AWARDS

MEDTECH QUALITY CHAMPION AWARDS is announced by Andhra Pradesh Medical Technology Zone (AMTZ) in collaboration with CII-Institute of Quality to facilitate organisations in the area of Quality, Innovation and Excellence.

The awards have four categories to encourage Quality initiatives with Med tech industries to meet the goal of achieve Atmanirbharta and achieve the goal of Government of India towards “Viksit Bharat-2047”.

About the Award

The MedTech Quality Champion Award recognizes and honors medical device organizations that demonstrate exceptional innovation, quality, and commitment to advancing healthcare through their products and services. This initiative not only aims to celebrate achievements but also to inspire a culture of excellence, driving organizations toward higher standards of quality and innovation.

Categories of Awards

The awards are divided into four categories:

  1. Micro and Small-Scale Enterprises
  2. Medium Enterprises
  3. Large-Scale Enterprises
  4. Service Sector Organizations

Eligibility Criteria

– Must be a legal entity in India with a minimum establishment of 2 years.
– Demonstrated a case study with application of Quality Tools & methodologies
– Relevant work completed within the last 2 years

Application Timelines

Last date for receipt of Application – 13th November 2024
Presentation by Companies – 19th to 21st November 2024
Award announcement – 27th November 2024

Visit www.cii-iq.in to download the application form and email to nidhi.barve@cii.in and karthik.v@amtz.in to submit your registrations

Award Presentation

Winners will be recognized at the CII Excellence Summit on 27 – 28 November 2024, attended by industry leaders and experts, fostering a spirit of collaboration and innovation in the MedTech sector.

Contact Details:

Nidhi Barve
Counsellor – Institute of Quality
nidhi.barve@cii.in
+91-9967950770

Karthik Raj V
Scientist B, AMTZ
karthik.v@amtz.in
+91-96771 63469

Click here for Brochure
Click here for Application

Source:
https://cii-iq.in/
https://www.amtz.in/

Share